share_log

Oppenheimer Assumes Evaxion Biotech at Outperform, Announces Price Target of $16

Oppenheimer Assumes Evaxion Biotech at Outperform, Announces Price Target of $16

奧本海默假設Evaxion Biotech表現跑贏大盤,宣佈目標股價爲16美元
Benzinga Real-time News ·  2022/07/18 10:34

Oppenheimer analyst Jeff Jones assumes Evaxion Biotech (NASDAQ:EVAX) with a Outperform rating and announces Price Target of $16.

奧本海默分析師傑夫·瓊斯假設Evaxion Biotech(納斯達克股票代碼:EVAX)的評級爲跑贏大盤,並宣佈目標股價爲16美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論